Caris Life Sciences (CAI) Stock Price Target 2026

The average analyst price target for Caris Life Sciences is $31.36, 30.1% above the current price. Of 11 analysts, 8 rate it Buy and 3 Hold. Targets range from $25 to $38. The latest change came on Nov 10, 2026, when Piper Sandler raised its price target on Caris Life Sciences from $22 to $25 and kept a Neutral rating.

The Average Analyst Price Target for Caris Life Sciences is $31.36.

Price Target Range — 6 Quarters

Analyst Consensus — 11 Analysts

8Buy

3Hold

Consensus RatingBuy# Analysts11Avg. Consensus PT$31.36Upside to Avg. PT+30.1%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Caris Life Sciences Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 10, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$22→$25
Nov 6, 2026	Citigroup	Albert Hu	PT Raise	Buy	$28→$36
Nov 5, 2026	TD Cowen	Dan Brennan	PT Raise	Buy	$36→$38
Nov 5, 2026	BTIG	Mark Massaro	Maintained	Buy	$38
Oct 27, 2026	BTIG	Mark Massaro	PT Raise	Buy	$33→$38
Oct 19, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Hold	$22→$30
Oct 14, 2026	JP Morgan	Casey Woodring	PT Raise	Overweight	$25→$35
Oct 13, 2026	TD Cowen	Dan Brennan	PT Raise	Buy	$30→$36
Sep 9, 2026	UBS	Doug Schenkel	Initiate	Neutral	$28
Aug 6, 2026	BTIG	Mark Massaro	PT Raise	Buy	$32→$33
Aug 6, 2026	Evercore ISI Group	Vijay Kumar	PT Raise	Outperform	$25→$26
Aug 5, 2026	JP Morgan	Casey Woodring	PT Cut	Overweight	$30→$25
Jul 6, 2026	Evercore ISI Group	Vijay Kumar	PT Cut	Outperform	$30→$25
Jul 2, 2026	BTIG	Mark Massaro	Maintained	Buy	$32
Jun 2, 2026	Wolfe Research	Mike Polark	Assumes	Peer Perform	—
May 8, 2026	Citigroup	Patrick Donnelly	PT Cut	Buy	$35→$28
May 8, 2026	JP Morgan	Casey Woodring	PT Cut	Overweight	$35→$30
May 8, 2026	BTIG	Mark Massaro	PT Cut	Buy	$38→$32
Apr 13, 2026	Jefferies	Tycho Peterson	Initiate	Buy	$28
Apr 10, 2026	Piper Sandler	David Westenberg	Initiate	Neutral	$21